Author

Ingelman-Sundberg Magnus

Karolinska Institutet - Cited by 57,262 - Pharmacogenomics - liver diseases - DILI

Biography

Professor of Molecular Toxicology since 1996 and research group leader in Pharmacogenetics at the Department of Physiology and Pharmacology since 2006. Section Head. Research description New genetic factors are identified that may pose pharmacogenomic biomarkers for individualization of drug therapy. Currently special emphasis is but on the role of rare alleles. Dedifferentiation and differentiation of hepatocytes studied with respect to mechanisms. 
Title
Cited by
Year
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models
RJ Weaver, EA Blomme, AE Chadwick, IM Copple, HHJ Gerets, ...Nature Reviews Drug Discovery 19 (2), 131-148, 2020202
136
2020
Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis
F Milosavljević, N Bukvić, Z Pavlović, Č Miljević, V Pešić, E Molden, ...JAMA psychiatry 78 (3), 270-280, 2021202
87
2021
Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?
R Van Westrhenen, KJ Aitchison, M Ingelman-Sundberg, MM JukićFrontiers in Psychiatry 11, 94, 2020202
82
2020
CYP2E1 in alcoholic and non-alcoholic liver injury. Roles of ROS, reactive intermediates and lipid overload
R Harjumäki, CS Pridgeon, M Ingelman-SundbergInternational journal of molecular sciences 22 (15), 8221, 2021202
64
2021
Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements
R Shekhani, L Steinacher, JJ Swen, M Ingelman‐SundbergClinical Pharmacology & Therapeutics 107 (5), 1240-1255, 2020202
54
2020
Pharmacogenetics in psychiatry: an update on clinical usability
RHN Van Schaik, DJ Müller, A Serretti, M Ingelman-SundbergFrontiers in Pharmacology 11, 575540, 2020202
50
2020
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ...The Lancet 401 (10374), 347-356, 2023202
49
2023
Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis
T Hurrell, V Kastrinou-Lampou, A Fardellas, DFG Hendriks, Å Nordling, ...Cells 9 (4), 964, 2020202
41
2020
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
M van der Lee, WG Allard, RHAM Vossen, RF Baak-Pablo, R Menafra, ...Science translational medicine 13 (603), eabf3637, 2021202
40
2021
Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation
VM Lauschke, M Ingelman-SundbergNPJ genomic medicine 5 (1), 9, 2020202
40
2020
Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients
LS Bråten, T Haslemo, MM Jukic, M Ingelman-Sundberg, E Molden, ...Neuropsychopharmacology 45 (3), 570-576, 2020202
33
2020
A 3D Cell Culture Model Identifies Wnt/β‐Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration
N Oliva‐Vilarnau, SU Vorrink, M Ingelman‐Sundberg, VM LauschkeAdvanced Science 7 (15), 2000248, 2020202
31
2020
Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three‐dimensional spheroid cultures of primary human hepatocytes
DFG Hendriks, SU Vorrink, T Smutny, SC Sim, Å Nordling, S Ullah, ...Clinical Pharmacology & Therapeutics 108 (4), 844-855, 2020202
27
2020
A novel CYP2C‐haplotype associated with ultrarapid metabolism of escitalopram
LS Bråten, T Haslemo, MM Jukic, M Ivanov, M Ingelman‐Sundberg, ...Clinical Pharmacology & Therapeutics 110 (3), 786-793, 2021202
27
2021
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
CH van der Wouden, S Böhringer, E Cecchin, KC Cheung, ...Pharmacogenetics and Genomics 30 (6), 131, 2020202
26
2020
3D human liver spheroids for translational pharmacology and toxicology
M Ingelman‐Sundberg, VM LauschkeBasic & clinical pharmacology & toxicology 130, 5-15, 2022202
24
2022
Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates
MM Jukić, RL Smith, E Molden, M Ingelman‐SundbergClinical Pharmacology & Therapeutics 110 (3), 750-758, 2021202
23
2021
Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearance
J Riede, BM Wollmann, E Molden, M Ingelman-SundbergDrug Metabolism and Disposition 49 (7), 501-508, 2021202
18
2021
Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism
T Smutny, L Hyrsova, A Braeuning, M Ingelman-Sundberg, P PavekArchives of Toxicology 95, 11-25, 2021202
15
2021
A unifying model to predict variable drug response for personalised medicine
M van der Lee, WG Allard, RHAM Vossen, RF Baak-Pablo, R Menafra, ...Biorxiv, 2020.03. 02.967554, 2020202
13
2020

Referred From: https://scholar.google.com/citations?user=KYD3usIAAAAJ&hl=en

Cited by
Citations 57262
h-index 126
i10-index 478
Recommended Journals
Open Access Journals